Trial Profile
Open Clinical Trial, uncontrolled, dose escalation, the application of IGBC-300 in microinvasive cancer, carcinoma in situ and severe dysplasia of the cervix.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs CIGB 300 (Primary)
- Indications Cervical cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms CERVISEG-300-I
- 20 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry record
- 14 Sep 2011 New trial record